Drugs / Ad4-mgag
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02771730 | Mar 2015 → Feb 2017 | — | Emergent BioSolutions | Terminated | No outcome recorded |
| Phase 1 | NCT01989533 | Nov 2013 → Apr 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad4-mgag | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01989533 ↗ |
| Modality | Vaccine | “live, replication-competent recombinant Adenovirus type 4-HIV vaccine regimens” NCT01989533 ↗ |
| Route | Oral | “delivered orally” NCT01989533 ↗ |